Topic： Navigating New Territories in Immuno-Oncology Through the Development of Multi-functional Fc-linked Immunomodulating Chimeras (FLIM-X)

Dr. Scott Liu founded HanchorBio Inc. in late 2020 in Taipei. As a global clinical stage biopharmaceutical company, HanchorBio focuses on developing  innovative immuno-oncology therapies. The founding team comprises  scientists with over 30 years of experience in biomedical research and drug  development, along with seasoned management professionals with over 25  years of industry expertise, all dedicated to reactivating the immune system to  fight cancer. HanchorBio’s proprietary " Fc-linked Immunomodulating Chimeras (FLIM-X)" platform enables the development of multifunctional biologics with diverse  targeting mechanisms, activating both the innate and adaptive immune  systems to combat tumors. These novel biologics demonstrate potential in  treating both solid tumors and hematologic cancers. Through innovative  molecular designs and optimized Chemistry, Manufacturing, and Controls  (CMC) processes, HanchorBio strives to address unmet medical needs in  oncology while making cancer treatments more accessible and affordable. Currently, HanchorBio has over eight biologics in development based on the  FLIM-X platform. The first and second in-house developed biologics have successfully entered clinical trials, with additional candidates expected to  follow soon. HanchorBio stands out as one of the few Taiwanese companies capable of  independent biologic drug innovation. Remarkably, the company advanced its  first biologic, HCB101, into clinical trials within just 2.3 years—a process that  typically takes around 5.5 years for most biopharma companies. In 2023 and  2024, HanchorBio received Investigational New Drug (IND) clearances from  the U.S. FDA, Taiwan TFDA, and China NMPA, enabling global clinical  development. HCB101 entered Phase I clinical trials in October 2023, testing its anti-cancer  effects in patients with solid tumors and hematologic malignancies across  hospitals in the United States, China, and Taiwan. To date, no severe adverse  events related to HCB101 have been reported. Additionally, among the 31 subjects enrolled in the study, 7 have demonstrated stable disease (SD), indicating their tumors remained controlled without further progression. Notably, 1 subject achieved a partial response (PR), reflecting a significant reduction in tumor size. In particular, a patient with non-Hodgkin lymphoma (NHL) experienced up to a 30% tumor shrinkage following HCB101 treatment, highlighting the promising antitumor activity observed in this early clinical stage.